|
1
|
Zieger K, Marcussen N, Borre M, Orntoft TF
and Dyrskjot L: Consistent genomic alterations in carcinoma in situ
of the urinary bladder confirm the presence of two major pathways
in bladder cancer development. Int J Cancer. 125:2095–2103. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar
|
|
3
|
Lamm D, Herr H, Jakse G, Kuroda M, Mostofi
FK, Okajima E, Sakamoto A, Sesterhenn I and da Silva FC: Updated
concepts and treatment of carcinoma in situ. Urol Oncol. 4:130–138.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parker WP, Ho PL, Melquist JJ, Scott K,
Holzbeierlein JM, Lopez-Corona E, Kamat AM and Lee EK: The effect
of concomitant carcinoma in situ on neoadjuvant chemotherapy for
urothelial cell carcinoma of the bladder: Inferior pathological
outcomes but no effect on survival. J Urol. 193:1494–1499. 2015.
View Article : Google Scholar
|
|
5
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shelley MD, Jones G, Cleves A, Wilt TJ,
Mason MD and Kynaston HG: Intravesical gemcitabine therapy for
non-muscle invasive bladder cancer (NMIBC): A systematic review.
BJU Int. 109:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uchiumi T, Kohno K, Tanimura H, Hidaka K,
Asakuno K, Abe H, Uchida Y and Kuwano M: Involvement of protein
kinase in environmental stress-induced activation of human
multidrug resistance 1 (MDR1) gene promoter. FEBS Lett. 326:11–16.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asakuno K, Kohno K, Uchiumi T, Kubo T,
Sato S, Isono M and Kuwano M: Involvement of a DNA binding protein,
MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D.
Biochem Biophys Res Commun. 199:1428–1435. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohga T, Uchiumi T, Makino Y, Koike K, Wada
M, Kuwano M and Kohno K: Direct involvement of the Y-box binding
protein YB-1 in genotoxic stress-induced activation of the human
multidrug resistance 1 gene. J Biol Chem. 273:5997–6000. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koike K, Uchiumi T, Ohga T, Toh S, Wada M,
Kohno K and Kuwano M: Nuclear translocation of the Y-box binding
protein by ultraviolet irradiation. FEBS Lett. 417:390–394. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okamoto T, Izumi H, Imamura T, Takano H,
Ise T, Uchiumi T, Kuwano M and Kohno K: Direct interaction of p53
with the Y-box binding protein, YB-1: A mechanism for regulation of
human gene expression. Oncogene. 19:6194–6202. 2000. View Article : Google Scholar
|
|
12
|
Stein U, Jürchott K, Walther W, Bergmann
S, Schlag PM and Royer HD: Hyperthermia-induced nuclear
translocation of transcription factor YB-1 leads to enhanced
expression of multidrug resistance-related ABC transporters. J Biol
Chem. 276:28562–28569. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holm PS, Bergmann S, Jurchott K, Lage H,
Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbelstein M, Dietel M,
et al: YB-1 relocates to the nucleus in adenovirus-infected cells
and facilitates viral replication by inducing E2 gene expression
through the E2 late promoter. J Biol Chem. 277:10427–10434. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sutherland BW, Kucab J, Wu J, Lee C,
Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, et al:
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in
the cold shock domain and affects the anchorage-independent growth
of breast cancer cells. Oncogene. 24:4281–4292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang YF, Homer C, Edwards SJ, Hananeia L,
Lasham A, Royds J, Sheard P and Braithwaite AW: Nuclear
localization of Y-box factor YB1 requires wild-type p53. Oncogene.
22:2782–2794. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guay D, Gaudreault I, Massip L and Lebel
M: Formation of a nuclear complex containing the p53 tumor
suppressor, YB-1, and the Werner syndrome gene product in cells
treated with UV light. Int J Biochem Cell Biol. 38:1300–1313. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Homer C, Knight DA, Hananeia L, Sheard P,
Risk J, Lasham A, Royds JA and Braithwaite AW: Y-box factor YB1
controls p53 apoptotic function. Oncogene. 24:8314–8325. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Birbach A, Gold P, Binder BR, Hofer E, de
Martin R and Schmid JA: Signaling molecules of the NF-kappa B
pathway shuttle constitutively between cytoplasm and nucleus. J
Biol Chem. 277:10842–10851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomas M, Pim D and Banks L: The role of
the E6-p53 interaction in the molecular pathogenesis of HPV.
Oncogene. 18:7690–7700. 1999. View Article : Google Scholar
|
|
20
|
Cooper MJ, Haluschak JJ, Johnson D,
Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G and Tan J: p53
mutations in bladder carcinoma cell lines. Oncol Res. 6:569–579.
1994.PubMed/NCBI
|
|
21
|
Hinata N, Shirakawa T, Zhang Z, Matsumoto
A, Fujisawa M, Okada H, Kamidono S and Gotoh A: Radiation induces
p53-dependent cell apoptosis in bladder cancer cells with
wild-type-p53 but not in p53-mutated bladder cancer cells. Urol
Res. 31:387–396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong RP, Tsang WP, Chau PY, Co NN, Tsang
TY and Kwok TT: p53-R273H gains new function in induction of drug
resistance through down-regulation of procaspase-3. Mol Cancer
Ther. 6:1054–1061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahmed M and Jamil J: Cytotoxicity of
neoplastic drugs Gefitinib, Cisplatin, 5-FU, Gemcitabine, and
Vinorelbine on human cervical cancer cells (HeLa). Biol Med.
3:60–71. 2012.
|
|
24
|
Evdokimova V, Ruzanov P, Anglesio MS,
Sorokin AV, Ovchinnikov LP, Buckley J, Triche TJ, Sonenberg N and
Sorensen PH: Akt-mediated YB-1 phosphorylation activates
translation of silent mRNA species. Mol Cell Biol. 26:277–292.
2006. View Article : Google Scholar :
|
|
25
|
Zhu J, Sammons MA, Donahue G, Dou Z,
Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW,
Shilatifard A, et al: Gain-of-function p53 mutants co-opt chromatin
pathways to drive cancer growth. Nature. 525:206–211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Esrig D, Spruck CH III, Nichols PW,
Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA and
Cote RJ: p53 nuclear protein accumulation correlates with mutations
in the p53 gene, tumor grade, and stage in bladder cancer. Am J
Pathol. 143:1389–1397. 1993.PubMed/NCBI
|
|
27
|
Grimm MO, Jürgens B, Schulz WA, Decken K,
Makri D and Schmitz-Dräger BJ: Inactivation of tumor suppressor
genes and deregulation of the c-myc gene in urothelial cancer cell
lines. Urol Res. 23:293–300. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsumura N, Nakamura Y, Kohjimoto Y,
Inagaki T, Nanpo Y, Yasuoka H, Ohashi Y and Hara I: The prognostic
significance of human equilibrative nucleoside transporter 1
expression in patients with metastatic bladder cancer treated with
gemcitabine-cisplatin-based combination chemotherapy. BJU Int.
108:E110–E116. 2011. View Article : Google Scholar
|
|
29
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
